+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oropharyngeal candidiasis in the era of antiretroviral therapy

Oropharyngeal candidiasis in the era of antiretroviral therapy

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 109(4): 488-495

Oropharyngeal candidiasis (OPC) remains a common problem in the HIV-infected population despite the availability of antiretroviral therapy (ART). Although Candida albicans is the most frequently implicated pathogen, other Candida species also may cause infection. The emergence of antifungal resistance within these causative yeasts, especially in patients with recurrent oropharyngeal infection or with long-term use of antifungal therapies, requires a working knowledge of alternative antifungal agents. Identification of the infecting organism and antifungal susceptibility testing enhances the ability of clinicians to prescribe appropriate antifungal therapy. Characterization of the responsible mechanisms has improved our understanding of the development of antifungal resistance and could enhance the management of these infections. Immune reconstitution has been shown to reduce rates of OPC, but few studies have evaluated the current impact of ART on the epidemiology of OPC and antifungal resistance in these patients. Preliminary results from an ongoing clinical study showed that in patients with advanced AIDS, oral yeast colonization was extensive, occurring in 81.1% of the 122 patients studied, and symptomatic infection occurred in one-third. In addition, resistant yeasts were still common, occurring in 25.3% of patients colonized with yeasts or with symptomatic infection. Thus, OPC remains a significant infection in advanced AIDS, even with ART. Current knowledge of the epidemiology, pathogenesis, clinical presentation, treatment, and mechanisms of antifungal resistance observed in OPC are important in managing patients with this infection and are the focus of this review.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054794487

Download citation: RISBibTeXText

PMID: 20156694

DOI: 10.1016/j.tripleo.2009.11.026

Related references

The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. Aids Research and Treatment 2012: 262471, 2012

Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. Aids 12(5): 538, 1998

Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. Aids 12(18): 2511-2513, 1998

Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology 113(3): 362-372, 2012

Therapy for oropharyngeal candidiasis in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 6(12): 1317-1318, 1993

Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. Aids Research and Human Retroviruses 15(18): 1619-1623, 1999

A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole. Mycoses 39(Suppl. 1): 123-126, 1996

Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. Aids 14(8): 979-985, 2000

Maintenance therapy of oropharyngeal candidiasis in HIV-infected patients with fluconazole. Aids 4(10): 1033-1034, 1990

Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 87(4): 437-441, 1999

Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. European Journal of Clinical Microbiology & Infectious Diseases 10(7): 598-599, 1991

Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. Journal of Acquired Immune Deficiency Syndromes 35(2): 144-150, 2004

Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. Aids 8(5): 708-709, 1994

Oropharyngeal candidiasis in patients receiving radiation therapy for head and neck cancer. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 458-459, 1998